CAMP4 Therapeutics Corporation (CAMP) vs Lyell Immunopharma, Inc. (LYEL)
CAMP4 Therapeutics Corporation and Lyell Immunopharma, Inc. are both Biotechnology companies. CAMP4 Therapeutics Corporation and Lyell Immunopharma, Inc. are of similar size ($248.0M and $241.0M). CAMP4 Therapeutics Corporation has the higher net margin (−2,543.7% vs −920,285.2%) and the higher return on invested capital (0.00% vs −539.5%). Across the 13 metrics below, CAMP4 Therapeutics Corporation leads on 9 and Lyell Immunopharma, Inc. on 4.
Valuation
Profitability
| Metric | CAMP | LYEL | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (1,254.22%) | (949,981.48%) | 0.00% |
| Net margin | (2,543.74%) | (920,285.19%) | 0.00% |
| Free cash flow margin | (680.36%) | (647,681.48%) | 0.00% |
| Return on equity | (545.85%) | (93.28%) | (57.72%) |
| Return on assets | (148.23%) | (71.34%) | (49.22%) |
| Return on invested capital | 0.00% | (539.53%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack